Published • loading... • Updated
European Commission Approves Roche's Susvimo for Wet AMD
Summary by Eyewire+
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
European Commission Approves Roche's Susvimo for Wet AMD
Key Takeaways The European Commission has approved Susvimo for wet AMD, providing continuous ranibizumab delivery through Roche’s refillable Contivue ocular implant Clinical data showed vision outcomes comparable with monthly intravitreal ranibizumab, while approximately 95% of patients receiving twice-yearly refills required no supplemental anti-VEGF treatment Roche is evaluating additional molecules for delivery through the Port Delivery Pla…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
